Alzinova improves manufacturing process of ALZ-101 to meet phase 2 requirements
Alzinova AB (publ) (FN STO: ALZ), a Swedish biopharma company developing disease-modifying treatments for Alzheimer’s, today announces that the manufacturing process for its oligomer-specific vaccine, ALZ-101, has been further improved to facilitate large-scale production.Alzinova’s drug substance manufacturing partner, Bachem (Bubendorf, Switzerland), has optimised the manufacturing process of the active ingredient in ALZ-101 – a vaccine in clinical development for the treatment of Alzheimer’s disease. Process optimisations have resulted in a more efficient and scalable manufacturing